Physician profile
Dawn E Yonkee
NPI 1912217464
$8,300.47
in general payments reported to CMS, 2019-2025
44 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,606 · 2022: $1,595 · 2023: $1,586 · 2024: $1,922 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,099.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,296.74 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,069.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $772.75 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $734.96 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $655.23 | 2021-2025 | Jardiance |
| Pfizer INC. | $651.17 | 2021-2025 | |
| Amgen INC. | $340.34 | 2021-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $293.29 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $266.37 | 2022-2025 | |
| Glaxosmithkline, LLC. | $216.56 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $201.33 | 2021 | |
| Amarin Pharma, INC. | $156.67 | 2021-2022 | |
| Abbott Laboratories | $136.82 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $133.74 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $129.98 | 2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $127.13 | 2021-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.32 | 2022-2024 | Xifaxan |
| Daiichi Sankyo INC. | $81.61 | 2021-2022 | |
| Esperion Therapeutics, INC. | $77.95 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $63.17 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $62.81 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $59.62 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Sumitomo Pharma America, INC. | $58.23 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $57.95 | 2021-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $52.67 | 2021-2023 | |
| Corcept Therapeutics | $49.15 | 2024 | Korlym |
| Eisai INC. | $44.74 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $34.08 | 2021 | |
| Sunovion Pharmaceuticals INC. | $32.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.89 | 2021 | |
| Arbor Pharmaceuticals, INC. | $29.36 | 2021 | |
| Stryker Corporation | $29.33 | 2025 | Clottriever Bold Catheter |
| Kowa Pharmaceuticals America, INC. | $27.19 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $24.07 | 2023 | Rexulti |
| Azurity Pharmaceuticals, INC. | $23.80 | 2023 | Edarbi |
| Shield Therapeutics INC | $22.79 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.75 | 2025 | Caplyta |
| Si-Bone, INC. | $21.71 | 2023 | |
| Mylan Specialty L.P. | $21.57 | 2021 | |
| Nevro Corp. | $18.68 | 2023 | Senza |
| Silk Road Medical, INC. | $18.53 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Alnylam Pharmaceuticals INC. | $16.64 | 2025 | Givlaari |
| Lucid Diagnostics INC. | $14.84 | 2024 | |
| Genentech USA, INC. | $6.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Yonkee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.